{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Pancreatic+Cancer&page=2", "query": { "condition": "Locally Advanced Pancreatic Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Pancreatic+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T13:45:55.432Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05945823", "title": "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Siewert Type 1 GEJ Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Futibatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2023-07-13", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-06-25T13:45:55.432Z", "location_count": 16, "location_summary": "Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05945823" }, { "nct_id": "NCT04539808", "title": "NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8", "Stage I Pancreatic Cancer American Joint Committee on Cancer v8", "Stage III Pancreatic Cancer American Joint Committee on Cancer v8", "Stage IV Pancreatic Cancer American Joint Committee on Cancer v8" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Losartan Potassium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2021-05-27", "completion_date": "2027-01-05", "has_results": true, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-06-25T13:45:55.432Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04539808" }, { "nct_id": "NCT01903083", "title": "Chemoimmunotherapy and Radiation in Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Malignant Neoplasm" ], "interventions": [ { "name": "Tadalafil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Pancreaticoduodenectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-07", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2018-02-01", "last_synced_at": "2026-06-25T13:45:55.432Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01903083" }, { "nct_id": "NCT00024427", "title": "Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Pancreatic Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "triacetyluridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wellstat Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2001-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-06-28", "last_synced_at": "2026-06-25T13:45:55.432Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Burbank, California • Duarte, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024427" }, { "nct_id": "NCT01485744", "title": "LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 39, "start_date": "2011-12", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2020-08-04", "last_synced_at": "2026-06-25T13:45:55.432Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485744" }, { "nct_id": "NCT01926197", "title": "Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5FU", "type": "DRUG" }, { "name": "Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2013-08-14", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2022-10-28", "last_synced_at": "2026-06-25T13:45:55.432Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01926197" }, { "nct_id": "NCT02210559", "title": "A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer (Unresectable)" ], "interventions": [ { "name": "FG-3019", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2014-07-31", "completion_date": "2021-12-15", "has_results": true, "last_update_posted_date": "2023-03-02", "last_synced_at": "2026-06-25T13:45:55.432Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02210559" }, { "nct_id": "NCT05512377", "title": "Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Neoplasms", "Solid Tumors", "Biliary Tract Cancer", "Lung Neoplasms", "Bladder Cancer" ], "interventions": [ { "name": "brigimadlin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2022-12-13", "completion_date": "2025-09-25", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-06-25T13:45:55.432Z", "location_count": 18, "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05512377" }, { "nct_id": "NCT00324428", "title": "TMS for the Treatment of Pancreatic Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pain", "Visceral Pain", "Pancreatic Cancer" ], "interventions": [ { "name": "Transcranial Magnetic Stimulation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 3, "start_date": "2006-05", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-06-25T13:45:55.432Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324428" }, { "nct_id": "NCT03614910", "title": "Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Nanoknife Irreversible Electroporation", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Holy Name Medical Center, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-05-15", "completion_date": "2021-05-01", "has_results": false, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-06-25T13:45:55.432Z", "location_count": 1, "location_summary": "Teaneck, New Jersey", "locations": [ { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03614910" } ] }